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Abstract
Objective: We aimed to investigate how lean body mass is related to circulating Interleukin 18 (IL-18) and its association
with metabolic syndrome (MetS) among apparently healthy Chinese.
Methods: A population-based sample of 1059 Chinese men and women aged 35–54 years was used to measure plasma IL-
18, glucose, insulin, lipid profile, inflammatory markers and high-molecular-weight (HMW)-adiponectin. Fat mass index (FMI)
and lean mass index (LMI) were measured by dual-energy X-ray absorptiometry. MetS was defined by the updated National
Cholesterol Education Program Adult Treatment Panel III criteria for Asian-Americans.
Results: Circulating IL-18 was positively correlated with LMI after adjustment for FMI (correlation coefficient=0.11,
P,0.001). The association with the MetS (odds ratio 3.43, 95% confidence interval 2.01–5.85) was substantially higher in the
highest than the lowest quartile of IL-18 after multiple adjustments including body mass index. In the stratified multivariable
regression analyses, the positive association between IL-18 and MetS was independent of tertiles of FMI, inflammatory
markers and HMW-adiponectin, but significantly interacted with tertile of LMI (P for interaction=0.010).
Conclusion: Elevated plasma IL-18 was associated with higher MetS prevalence in apparently healthy Chinese, independent
of traditional risk factors, FMI, inflammatory markers and HMW-adiponectin. More studies are needed to clarify the role of
lean mass in IL-18 secretion and its associated cardio-metabolic disorders.
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Introduction
Growing evidence suggests a pivotal role of chronic subclinical
inflammation in the pathophysiology of cardio-metabolic disorders
[1]. As an active endocrine organ, human adipose tissue secretes
multiple pro-inflammatory cytokines, including interleukin 6 (IL-
6), tumor necrosis factor (TNF)-a, monocyte chemoattractant
protein-1 (2), and IL-18 (3).
Discovered in 1989 as an interferon-c–inducing factor (4), IL-18
is now recognized as a pleiotropic cytokine related with both
innate and acquired immune responses (5). Synergistically with IL-
12, IL-18 could induce interferon-c production from T, B and
natural killer cells (6). It also plays a crucial role in pro-
inflammatory cascade by stimulating the production of TNF-a
and IL-6 (4,7). Elevated IL-18 concentration provided additional
information over C-reactive protein (CRP), IL-6 and fibrinogen in
predicting cardiovascular mortality for patients with coronary
artery disease (8) or incident of coronary events among healthy
men (9). Exiting evidence also indicated that circulating IL-18 was
positively associated with insulin resistance, metabolic syndrome
(MetS) and type 2 diabetes (10–13), suggesting potential
applications of IL-18 as an intervention target or prognostic
biomarker. However, most studies to date were conducted in
western populations and little is known about the effect of IL-18 on
cardio-metabolic risk in Asians like Chinese who might have
different metabolic susceptibility (14).
Although adipose tissue is believed as one of important sources
for IL-18 (3), effects of different body compartments on this pro-
inflammatory marker remain controversial. For instance, body
mass index (BMI), waist circumference, waist-to-hip ratio, body fat
mass and/or fat percentage (fat mass/total body weight) were
correlated with levels of IL-18 in some (11,13,15,16), but not in
other studies (9,10,12,17). Meanwhile, weight loss following
lifestyle changes significantly reduced circulating IL-18 (18,19).
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free mass rather than fat mass was positively associated with serum
IL-18 (10). Moreover, TNF-a infusion in men enhanced IL18
mRNA expression in muscles, but not in adipose tissues (20),
implicating potential involvement of muscle mass in generating IL-
18. However, few studies evaluated specific effects of different
body compartments, distinguished by fat mass and lean mass, on
relationship between circulating IL-18 and cardio-metabolic
disorders. Therefore, we aimed firstly to investigate the relation-
ships between different body compartments with plasma IL-18
and also its association with the MetS; secondly to evaluate to what
extent the association was mediated by body-size adjusted lean
mass or fat mass, as well as adipokine and inflammation in
apparently healthy Chinese men and women.
Methods
Ethics Statement
The study was approved by the Institutional Review Board of
the Institute for Nutritional Sciences and written informed consent
was obtained from all participants.
Study population
The design and recruitment of the population-based case
(BMI$24.0 kg/m
2) and control (18#BMI,24.0 kg/m
2) study
were described in detail elsewhere [21]. Briefly, a total of 1059
(559 overweight/obese and 500 normal-weight) eligible partici-
pants aged 35–54 years were recruited from Shanghai, China.
Information on demographic variables, health status and behav-
iors was obtained using a standardized questionnaire [21].
Following a home interview, all participants were asked to fast
overnight before a physical examination. Body weight, height,
waist circumference and blood pressure were measured using a
standardized protocol [21]. Whole-body densitometry was con-
ducted under a Hologic DXA (QDR-4500, Hologic, Waltham,
MA, USA; software version 11.2.1).
Individuals without data of dual-energy X-ray absorptiometry
(DXA) scan or IL-18 (100, 9.4%), or presumably having acute
inflammation (CRP.10 mg/l, 18, 1.7%) were further excluded
and final analyses included 941 participants.
Laboratory methods
Fasting peripheral venous EDTA blood samples were collected
and centrifuged at 4uC. All plasma samples were stored at 280uC
until analyses. The measurements of total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides, glucose, glycohaemoglobin (HbA1c),
insulin, CRP, lipopolysaccharide binding protein (LBP), IL-6
and high-molecular-weight (HMW)-adiponectin were described
previously [21]. The insulin resistance index (homeostatic model
assessment of insulin resistance [HOMA-IR]) was calculated
according to updated homeostasis model assessment methods
(http://www.dtu.ox.ac.uk/).
Plasma IL-18 was analyzed by an ELISA kit from Medical
Biological Laboratories (Naku-ku, Nagoya, Japan). The assay has a
sensitivity of 12.5 pg/ml with a measurable concentration range of
25.6–1000 pg/ml. The intra-assay coefficients of variation (CV)
were 9.9%, 10.8% and 5.0% at 69.7, 345.5 and 2765.5 pg/ml,
respectively; while the inter-assay CVs were 6.3%, 5.2% and
10.1% at 160.1, 615.1 and 2621.1 pg/ml, respectively.
Definition of Metabolic Syndrome
MetS was defined based upon the updated National Cholesterol
Education Program Adult Treatment Panel III criteria for Asian-
Americans [22] as presenting at least 3 of the following
components: 1) Waist circumferences $90 cm in men or
$80 cm in women; 2) Triglycerides $1.7 mmol/l; 3) HDL
cholesterol ,1.03 mmol/l for men or ,1.30 mmol/l for women;
4) Blood pressure $130/85 mmHg, or current use of anti-
hypertensive medications; and 5) Fasting plasma glucose
$5.6 mmol/l.
Modified MetS was defined as having 2 or more components of
MetS without central obesity.
Calculation of fat mass index and lean mass index
Using fat mass, fat-free mass and bone mass measured by DXA,
fat mass index (FMI), and lean mass index (LMI) were calculated
as follows and were normalized for body size [23]:
FMI=fat mass/height
2;
LMI=lean mass/height
2=(fat-free mass2bone mineral
content) /height
2.
Statistical analyses
Log-transformations were performed for IL-18, triglycerides,
insulin, HOMA-IR, CRP, IL-6, LBP, and HMW-adiponectin to
approximate normality. Analysis of covariance for continuous
variables and logistic regression models for categorical variables
were applied for the comparison across IL-18 quartiles. Partial
Spearman correlation coefficients between IL-18 and body
composition, metabolic features and cytokines were calculated
by adjustment for age, sex and BMI (not for body composition
data). The correlations between IL-18 and FMI or LMI were
further adjusted for LMI or FMI (mutually adjusted for each
other).
Multivariate logistic regression models were applied to estimate
the odds ratios (ORs) for MetS. Adjusted potential confounders
included age, sex, lifestyle factors, education level, family history of
chronic diseases and BMI, as well as CRP, IL-6, LBP, and HMW-
adiponectin. In sex-stratified models, menopause status and
hormone use were further controlled in women. The ORs for
MetS according to joint classification of IL-18 and FMI, LMI and
cytokines were also calculated. Data management and statistical
analyses were performed using Stata 9.2 (Stata, College Station,
TX). Statistical tests were two-sided and P value,0.05 was
considered statistically significant.
Results
Baseline characteristics
Overweight/obese participants had significantly higher plasma
IL-18 levels than their normal-weight counterparts (geometric
mean 240.7 (95% confidence interval 232.8–248.8) pg/ml vs.
208.1 (200.7–215.9) pg/ml, respectively; P,0.001). Subjects with
higher IL-18 concentrations were more likely to be males and
alcohol drinkers, and had higher prevalence of MetS, elevated
levels of BMI, waist circumference, blood pressure, glucose,
HbA1c, insulin, HOMA-IR and triglycerides, and lower concen-
trations of HDL cholesterol (all P,0.05, Table 1). They also
showed higher CRP, IL-6 and LBP, but lower HMW-adiponectin
levels (all P,0.01, Table 1).
Association between IL-18 concentrations and body
composition parameters
In the whole sample, plasma IL-18 was positively correlated
with BMI, waist circumference, total body fat mass/percentage,
total body lean mass, FMI and LMI after controlling for age and
Interleukin 18 and Metabolic Syndrome
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(mutually adjusted for each other) only abolished the significant
correlations of IL-18 with FMI (r=0.04, P.0.05), but not with
LMI (r=0.11, P,0.001).
IL-18 was also correlated with blood pressure, HDL cholesterol,
triglycerides, insulin, HOMA-IR, inflammatory markers and
HMW-adiponectin (all P,0.01, Table 2). The correlations of
most metabolic traits were more pronounced in females and
overweight/obese subjects than in their male and normal-weight
counterparties.
Association between IL-18 concentrations and metabolic
syndrome
Overall, the ORs for MetS increased progressively across the
IL-18 quartiles (P,0.001 for trend, Table 3) after adjusting for
age, sex, lifestyle factors, family history of chronic diseases and
BMI. The ORs for MetS comparing the highest with the lowest
IL-18 quartile were 3.43 (95% confidence interval 2.01–5.85)
(model 2). Additionally controlling for inflammatory markers
(CRP, IL-6, LBP) (model 3) and HMW-adiponectin (model 4),
the ORs of MetS and its components (elevated blood pressure and
low HDL cholesterol) were attenuated slightly, but remained
significant. Men and women showed similar trends for the IL-18-
MetS association (Table S1 and Table S2) without a significant
interaction between IL-18 and sex (P for interaction .0.05 for all
models).
In the stratified multivariable regression analyses, the positive
IL-18-MetS associations were independent of tertile of FMI, but
significantly interacted with tertile of LMI (P for interac-
tion=0.232 and 0.010, respectively) (Figure 1, A–B). When
further stratified by sex, significant interaction between IL-18 and
LMI was only observed in women (P for interaction=0.043)
(Figure S1). Moreover, high IL-18 concentrations seemed to
increase the ORs for MetS, regardless levels of CRP, IL-6, LBP
Table 1. Characteristics of participants across IL-18 quartile
a.
IL-18 quartile
Q1 (n=235) Q2 (n=235) Q3 (n=236) Q4 (n=235) P value
IL-18 (pg/ml)
b 136.9 (133.4–140.5) 199.0 (196.8–201.3) 257.0 (254.8–259.2) 363.3 (352.9–373.9) —
Age (yrs)
c 45.5 (5.4) 46.1 (5.4) 46.6 (5.2) 46.6 (5.3) 0.072
Men (n, %)
d 36 (15.3) 78 (33.2) 101 (42.8) 130 (55.3) ,0.001
Low physical activity (n, %) 123 (52.3) 115 (48.9) 110 (46.6) 121 (51.5) 0.593
Education levels (n, %) 0.171
0,9 yrs 66 (28.1) 61 (26.0) 54 (22.9) 69 (29.4)
10,12 yrs 119 (50.6) 129 (54.9) 129 (54.7) 127 (54.0)
.12 yrs 50 (21.3) 45 (19.2) 53 (22.5) 39 (16.6)
Current smoker (yes, n, %) 27 (11.5) 53 (22.6) 65 (27.5) 83 (35.3) 0.962
Alcohol drinker (yes, n, %) 74 (31.5) 85 (36.2) 79 (33.5) 99 (42.1) 0.039
Family history of chronic
diseases (n, %)
101 (43.0) 87 (37.0) 93 (39.4) 99 (42.1) 0.507
Metabolic syndrome (n, %) 56 (23.8) 91 (38.7) 106 (44.9) 137 (58.3) ,0.001
BMI (kg/m
2) 23.4 (3.7) 24.5 (3.9) 25.3 (4.4) 25.3 (3.9) ,0.001
Waist circumference (cm) 80.1 (10.1) 84.2 (10.5) 86.7 (11.6) 88.1 (11.1) ,0.001
Systolic blood pressure (mmHg) 119.1 (15.6) 124.2 (17.1) 126.4 (17.7) 128.4 (17.1) ,0.001
Diastolic blood pressure (mmHg) 75.1 (10.5) 78.9 (11.3) 80.8 (11.8) 82.2 (11.3) ,0.001
Glucose (mmol/l) 5.79 (0.85) 6.12 (1.53) 6.10 (1.08) 6.41 (1.81) ,0.001
HbA1c (%) 5.62 (0.51) 5.68 (0.84) 5.66 (0.60) 5.85 (0.84) 0.008
Insulin (mU/ml)
b 7.88 (7.35–8.45) 9.03 (8.43–9.68) 9.62 (8.99–10.29) 10.02 (9.35–10.74) ,0.001
HOMA-IR
b 0.91 (0.85–0.98) 1.06 (0.99–1.13) 1.12 (1.05–1.20) 1.18 (1.10–1.27) ,0.001
Total cholesterol (mmol/l) 5.26 (1.14) 5.33 (1.19) 5.35 (1.10) 5.27 (1.23) 0.856
LDL cholesterol (mmol/l) 3.20 (0.94) 3.36 (1.02) 3.36 (0.93) 3.34 (1.01) 0.501
HDL cholesterol (mmol/l) 1.56 (0.44) 1.41 (0.41) 1.37 (0.38) 1.24 (0.38) ,0.001
Triglycerides (mmol/l)
b 1.04 (0.97–1.12) 1.22 (1.13–1.32) 1.39 (1.29–1.49) 1.56 (1.43–1.69) ,0.001
CRP (mg/l)
b 0.64 (0.57–0.71) 0.83 (0.74–0.93) 1.09 (0.96–1.22) 1.10 (0.97–1.24) ,0.001
IL-6 (pg/ml)
b 1.22 (1.12–1.31) 1.34 (1.26–1.43) 1.51 (1.38–1.65) 1.57 (1.46–1.70) ,0.001
LBP (mg/ml)
b 10.2 (8.9–11.7) 15.1 (13.0–17.5) 20.7 (17.8–24.1) 20.1 (17.2–23.5) ,0.001
HMW-Adiponectin (mg/ml)
b 3.33 (2.99–3.72) 2.40 (2.14–2.69) 2.21 (1.93–2.53) 2.05 (1.82–2.31) 0.002
aData are unadjusted arithmetic means (SD), P values were calculated after adjustment for age and sex.
bData are unadjusted geometric means (95% CI).
cP value was calculated after adjustment for sex only.
dP value was calculated after adjustment for age only.
Percentages may not sum to 100 because of rounding.
doi:10.1371/journal.pone.0018104.t001
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and 0.922, respectively) (Figure 1, C–F).
Discussion
We found a strong association between elevated plasma IL-18
and the MetS prevalence, independent of lifestyle factors, BMI,
adipokine and inflammatory markers in apparently healthy
Chinese. These results suggested that IL-18-MetS association
might not be exclusively mediated by excess adiposity or associated
biomarkers, and lean mass might also play a potential role. To our
best knowledge, this is the first study to elucidate the effects of
body compartments, distinguished by FMI and LMI, on IL-18 and
its association with the MetS in Chinese.
Unlike the findings from most previous studies, we observed that
LMI, but not FMI was possitively correlated with plasma IL-18
(Table 2), suggesting lean mass as a potential source of IL-18.
Meanwhile, we also found significantly higher IL-18 levels in
overweight/obese individuals than in normal-weight counterparts,
consistent with the findings of others [18]. Excess adipose tissue was
viewed as a major source of circulating IL-18 in many studies when
BMI, containing the fractions of both fat and fat-free compartments
[24], was used in analyses. Thus the effect of fat mass on IL-18
generation might be confounded by lean mass or vice versa. Besides
adipocytes [3], non-adipocytes in adipose tissue could also secrete
IL-18 [25], while TNF-a infusion in men increased IL18 mRNA
expression in muscles but not in adipose tissue [20]. Another
plausible explanation for the discrepant results might be due to the
fact that body composition was measured by bioelectrical
impedance in some studies [10,17] but by DXA in others [15,16].
With more accurate measurement of DXA, particularly with large
sample size like the Dallas Heart Study (n=2231), both total of fat
or lean mass was significantly correlated with circulating IL-18 [16].
However, the two compartments were not mutually adjusted for
each other in that study, therefore it remains unclear to what degree
the correlations were explained by fat or lean mass.
Our study provides evidence that elevated plasma IL-18 was a
strong and independent risk factor of MetS (Table 3) and some of
its components among Chinese, similar to the observation in a
Caucasian population [11]. It was noteworthy that FMI, an
indicator of adiposity, did not show much appreciable effect. On
the contrary, the positive IL-18-MetS association was significantly
interacted with tertile of LMI. In fact, lean mass or fat-free mass
(combining both lean and bone masses) was previously suggested
to be associated with MetS and its components. For example,
obese women with MetS have more lean mass than those without
MetS [26]. The results from a population-based study in Chinese
showed that either fat or fat-free mass index was significantly and
Table 2. Partial spearman correlation coefficients between IL-18 and body composition, metabolic features and cytokines
a.
Total (n=941) Men (n=345) Women (n=596) Normal-weight(n=448) Overweight/obesity (n=493)
BMI 0.19
e 0.12
g 0.21
e 0.05 0.12
g
Waist circumference 0.20
e 0.12
g 0.23
e 0.08 0.13
f
Total body fat % 0.13
e 0.08 0.15
e 0.01 0.06
Total body fat mass 0.16
e 0.10 0.20
e 0.03 0.10
g
Total body lean mass 0.17
e 0.13
g 0.17
e 0.01 0.12
g
FMI 0.17
e 0.10 0.20
e 0.03 0.11
g
FMI
b 0.04 0.01 0.07 0.03 0.06
LMI 0.20
e 0.14
g 0.22
e 0.05 0.17
e
LMI
c 0.11
e 0.09 0.10
g 0.05 0.14
f
Systolic blood pressure
d 0.09
f 0.05 0.10
g 0.06 0.11
g
Diastolic blood pressure
d 0.11
e 0.06 0.12
f 0.10
g 0.10
g
Total cholesterol
d 20.03 0.02 20.05 20.01 20.05
HDL cholesterol
d 20.14
e 20.09 20.16
e 20.13
f 20.15
f
LDL cholesterol
d 20.01 0.01 20.03 0.01 20.03
Triglycerides
d 0.09
f 0.11
g 0.09
g 0.08 0.09
g
Fasting glucose
d 0.06 0.05 0.06 0.01 0.11
g
HbA1c
d 0.03 0.09 0.01 20.05 0.11
g
insulin
d 0.11
e 0.11
g 0.11
f 0.14
f 0.08
HOMA-IR
d 0.11
e 0.12
g 0.12
f 0.14
f 0.10
g
CRP
d 0.14
e 0.15
f 0.13
f 0.12
g 0.18
e
IL-6
d 0.11
f 0.08 0.11
f 0.14
f 0.06
LBP
d 0.15
e 0.13
g 0.15
e 0.12
g 0.19
e
HMW-Adiponectin
d 20.09
f 20.01 20.13
f 20.12
g 20.08
aAll correlation coefficients were calculated after adjustment for age and sex, P value not adjusted for sex in sex-stratified models;
bFurther adjusted for LMI;
cfurther adjusted for FMI;
dfurther adjusted for BMI.
eP,0.001,
fP,0.01,
gP,0.05.
doi:10.1371/journal.pone.0018104.t002
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metabolic inflexibility and insulin resistance in skeletal muscle are
thought to be major contributors to metabolic disorders [27].
Skeletal muscle insulin resistance in young healthy subjects could
promote atherogenic dyslipidemia at the early stage of MetS
independent of intra-abdominal obesity and adipokines [28].
Obviously, whether mechanistic link exists between circulating IL-
18 and skeletal muscle insulin resistance in pathogenesis of cardio-
metabolic disorders needs to be elucidated further.
As a pro-inflammatory cytokine, IL-18 could stimulate the
activation of NF-kB pathway and subsequently synthesize IL-6
and CRP [29]. However, even with significant correlation between
these inflammatory markers and IL-18 levels in current study
(Table 2), controlling for CRP and IL-6 did not substantially
change the IL-18-MetS association, in agreement with previous
studies [11,12]. Thus, one possibility is that IL-18 might act
through non-adiposity-related inflammatory pathways [13]. IL-18
is also a pleiotropic cytokine related with both innate and acquired
immune responses [5] and one of its native stimuli is subclinical
endotoxemia, indicated by low to moderately elevated circulating
lipopolysaccharide (LPS) derived from gram-negative bacteria [7].
Recently, we found a positive association between elevated LBP
and the MetS prevalence in this study population [21]. LBP plays
an essential role in recognizing LPS and triggering the
downstream inflammatory cascade. Therefore, it could be used
as a biomarker reflecting innate immune response triggered by
LPS [30]. However, the associations of MetS with LBP and IL-18
tended to be independent of each other in current analysis
Table 3. Odds ratios and 95% confidence interval for metabolic syndrome according to quartile of IL-18
a.
Quartile of IL-18
Q1 (IL-18#172.1
pg/ml)
Q2 (172.1,IL-18#228.5
pg/ml)
Q3 (228.5,IL-18#290.9
pg/ml)
Q4 (IL-18.290.9
pg/ml)
P for
trend
Metabolic syndrome 56/235 91/235 106/236 137/235
Model 1 1 1.92 (1.28–2.87) 2.38 (1.59–3.57) 4.00 (2.64–6.05) ,0.001
Model 2 1 1.63 (0.98–2.73) 1.54 (0.91–2.61) 3.43 (2.01–5.85) ,0.001
Model 3 1 1.64 (0.97–2.77) 1.36 (0.79–2.34) 3.18 (1.84–5.49) ,0.001
Model 4 1 1.56 (0.92–2.64) 1.36 (0.79–2.34) 3.10 (1.79–5.37) ,0.001
Central obesity 97/235 122/235 129/236 137/235
Model 1 1 1.60 (1.11–2.32) 1.83 (1.25–2.66) 2.20 (1.49–3.24) ,0.001
Model 2 1 1.04 (0.52–2.12) 0.71 (0.34–1.49) 1.16 (0.55–2.46) 0.929
Model 3 1 1.05 (0.51–2.16) 0.65 (0.31–1.38) 1.09 (0.51–2.31) 0.887
Model 4 1 1.03 (0.50–2.11) 0.64 (0.30–1.36) 1.07 (0.50–2.27) 0.858
Elevated blood pressure 59/235 90/235 104/236 134/235
Model 1 1 1.64 (1.09–2.46) 1.92 (1.28–2.88) 3.06 (2.03–4.63) ,0.001
Model 2 1 1.42 (0.92–2.21) 1.45 (0.93–2.28) 2.39 (1.52–3.75) ,0.001
Model 3 1 1.35 (0.87–2.12) 1.31 (0.83–2.06) 2.16 (1.37–3.40) 0.002
Model 4 1 1.35 (0.87–2.12) 1.31 (0.83–2.06) 2.16 (1.37–3.40) 0.002
Hypertriglyceridemia 51/235 67/235 83/236 98/235
Model 1 1 1.19 (0.77–1.83) 1.47 (0.96–2.25) 1.74 (1.13–2.67) 0.007
Model 2 1 0.97 (0.62–1.54) 1.05 (0.66–1.66) 1.26 (0.80–1.99) 0.264
Model 3 1 0.90 (0.56–1.43) 0.88 (0.55–1.40) 1.08 (0.68–1.73) 0.688
Model 4 1 0.82 (0.51–1.31) 0.83 (0.52–1.34) 0.99 (0.62–1.60) 0.869
Low HDL cholesterol 59/235 88/235 76/236 104/235
Model 1 1 1.98 (1.32–2.96) 1.66 (1.10–2.51) 2.95 (1.95–4.48) ,0.001
Model 2 1 1.71 (1.13–2.60) 1.24 (0.80–1.92) 2.36 (1.53–3.65) 0.001
Model 3 1 1.70 (1.11–2.58) 1.20 (0.77–1.87) 2.34 (1.51–3.63) 0.002
Model 4 1 1.55 (1.01–2.38) 1.14 (0.72–1.79) 2.16 (1.38–3.39) 0.005
Hyperglycemia 133/235 155/235 160/236 160/235
Model 1 1 1.50 (1.03–2.20) 1.62 (1.10–2.39) 1.67 (1.12–2.49) 0.012
Model 2 1 1.39 (0.94–2.05) 1.43 (0.96–2.14) 1.43 (0.95–2.17) 0.098
Model 3 1 1.41 (0.95–2.09) 1.39 (0.92–2.10) 1.40 (0.92–2.14) 0.142
Model 4 1 1.41 (0.95–2.10) 1.39 (0.92–2.10) 1.40 (0.92–2.14) 0.144
aMetabolic syndrome and its components were defined based upon the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian-
Americans.
Model 1, adjusted for age and sex;
Model 2, further adjusted for smoking, alcohol drinking, physical activity, education, family history of chronic diseases and BMI;
Model 3, further adjusted for inflammatory markers (CRP, IL-6 and LBP);
Model 4, further adjusted for HMW-adiponectin.
doi:10.1371/journal.pone.0018104.t003
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immune response might not exert large impact on the association
between IL-18 and the MetS prevalence.
Overall, the findings of our study have provided further insights
into the sources of IL-18 as well as modifying factors, particularly the
body-sized adjusted lean body mass, on the IL-18-MetS association.
However, owing to the cross-sectional design, no causal relation could
be established. The data were obtained from a case-control sample,
which might limit the finding of our study to be generalized in general
populations. Moreover, the measurement of body composition by
Figure 1. Odds ratio for metabolic syndrome according to joint classification of IL-18 and FMI (A), LMI (B) and cytokines (C–F). At o
B: Modified metabolic syndrome was defined as having 2 or more components of metabolic syndrome without central obesity. Adjusted for age, sex,
smoking, alcohol drinking, physical activity, education, family history of chronic diseases and LMI (A) or FMI (B). C to F: Adjusted for age, sex, smoking,
alcohol drinking, physical activity, education, family histories of chronic diseases and BMI.
doi:10.1371/journal.pone.0018104.g001
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subcutaneous adiposity. Nonetheless, additional controlling for
hepatic enzymes - markers of fatty liver, did not substantially change
the results (data not shown). Furthermore, we could not rule out the
possibility that the observed significant interaction between IL-18 and
lean body mass on the MetS might be by chance because of multiple
testing. Therefore, the findings for our study should be confirmed in
prospective studies and also in different populations.
Our study suggests a strong positive association between
circulating IL-18 levels and the MetS in apparently healthy
Chinese, independent of obesity, fat mass index, adipokine and
inflammation. More studies are needed to clarify the roles of lean
mass in generating IL-18 and also its relationship with cardio-
metabolic disorders.
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